Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01308567
Registration number
NCT01308567
Ethics application status
Date submitted
3/03/2011
Date registered
4/03/2011
Date last updated
5/06/2019
Titles & IDs
Public title
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
Query!
Scientific title
Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m^2 and at 20 mg/m^2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy
Query!
Secondary ID [1]
0
0
2010-022064-12
Query!
Secondary ID [2]
0
0
EFC11784
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FIRSTANA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Cabazitaxel (XRP6258)
Treatment: Drugs - Docetaxel (XRP6976)
Treatment: Drugs - Prednisone
Experimental: Cabazitaxel 25 mg/m^2 - Cabazitaxel 25 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.
Experimental: Cabazitaxel 20 mg/m^2 - Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
Active Comparator: Docetaxel 75 mg/m^2 - Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
Treatment: Drugs: Cabazitaxel (XRP6258)
Pharmaceutical form: Solution for injection; Route of administration: Intravenous
Treatment: Drugs: Docetaxel (XRP6976)
Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
Treatment: Drugs: Prednisone
Pharmaceutical form: Tablet; Route of administration: Oral
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant's last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [1]
0
0
Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months )
Query!
Secondary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [1]
0
0
Baseline up to tumor progression, PSA progression, pain progression or death (maximum duration: 51 months)
Query!
Secondary outcome [2]
0
0
Time to Tumor Progression Free Survival
Query!
Assessment method [2]
0
0
Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [2]
0
0
Baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Overall Objective Tumor Response
Query!
Assessment method [3]
0
0
Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Query!
Timepoint [3]
0
0
Baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Query!
Secondary outcome [4]
0
0
Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS)
Query!
Assessment method [4]
0
0
Time to PSA-PFS: time interval between date of randomization & first occurrence of PSA progression/ death, whichever was earlier. PSA progression:1) In PSA responders(=50% decline from baseline PSA of =10 ng/mL):increase of =25%(at least 2 ng/mL)over nadir value, confirmed by second PSA value at least 3 weeks later;2)In PSA non-responders(not achieved =50% decline from baseline PSA =10 ng/mL):increase of =25% (at least 2 ng/mL) over baseline value, confirmed by second PSA value at least 3 weeks later;3)In participants not eligible for PSA response(baseline PSA <10 ng/mL):(a)in participants with baseline PSA>0 ng/mL&<10 ng/mL: increase in PSA by 25% (at least 2 ng/mL) above baseline level, confirmed by second PSA value at least 3weeks apart;(b)in participants with baseline value=0ng/mL: a post baseline PSA value =2ng/mL.Early rise in PSA only indicated progression if it was associated with another sign of DP or if it continued beyond 12 weeks. Analysis performed by Kaplan-Meier method.
Query!
Timepoint [4]
0
0
Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With PSA Response
Query!
Assessment method [5]
0
0
PSA response was defined as =50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value =10 ng/mL.
Query!
Timepoint [5]
0
0
Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Query!
Secondary outcome [6]
0
0
Time to Pain Progression Free Survival (Pain PFS)
Query!
Assessment method [6]
0
0
Time to pain PFS was defined as the time interval between date of randomization and the date of the first occurrence of pain progression or death, whichever was earlier. Pain progression was defined as an increase of =1 point in the median present pain intensity (PPI) score from the nadir confirmed by a second assessment at least 3 weeks later or =25 % increase in the mean analgesic score from baseline, due to cancer related pain confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [6]
0
0
Baseline until disease progression, death or study cut-off date (maximum duration: 51 months)
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Pain Response
Query!
Assessment method [7]
0
0
Pain response was defined as either a =2-point decrease from baseline median PPI score without increase in analgesic score, or a =50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score=10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.
Query!
Timepoint [7]
0
0
Baseline until pain progression, death or study cut-off date (maximum duration: 51 months)
Query!
Secondary outcome [8]
0
0
Skeletal Related Events (SRE) Free Survival
Query!
Assessment method [8]
0
0
SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [8]
0
0
Baseline until occurrence of first SRE or death (maximum duration: 51 months)
Query!
Secondary outcome [9]
0
0
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL)
Query!
Assessment method [9]
0
0
FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.
Query!
Timepoint [9]
0
0
Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)
Query!
Secondary outcome [10]
0
0
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL
Query!
Assessment method [10]
0
0
FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.
Query!
Timepoint [10]
0
0
Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)
Query!
Eligibility
Key inclusion criteria
Inclusion criteria :
- I 01. Histologically- or cytologically-confirmed prostate adenocarcinoma.
- I 02. Metastatic disease.
- I 03. Progressive disease while receiving hormonal therapy or after surgical
castration.
- I 04. Effective castration (serum testosterone levels =0.50 ng/mL) by orchiectomy
and/or luteinizing hormone-releasing hormone (LHRH) agonists or antagonist with or
without anti-androgens.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- E 01. Prior chemotherapy for prostate cancer,
- E 02. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy
or surgery to the time of randomization. Participants on biphosphonates prior to study
entry.
- E 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of
bone marrow.
- E 04. Adverse events (excluding alopecia and those listed in the specific exclusion
criteria) from any prior anticancer therapy of grade >1(National Cancer Institute
Common Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.
- E 05. Less than 18 years (or country's legal age of majority if the legal age is >18
years).
- E 06. Eastern Cooperative Oncology Group (ECOG) performance status >2.
- E 07. History of brain metastases, uncontrolled spinal cord compression, or
carcinomatous meningitis or new evidence of brain or leptomeningeal disease.
- E 08. Prior malignancy.
- E 09. Participation in another clinical trial and any concurrent treatment with any
investigational drug within 30 days prior to randomization.
- E 10. Any of the following within 6 months prior to study enrollment: myocardial
infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,
New York Heart Association (NYHA) class III or IV congestive heart failure, stroke or
transient ischemic attack.
- E 11. Any of the following within 3 months prior to randomization: treatment resistant
peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory
bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled
thromboembolic event.
- E 12. Acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease
requiring antiretroviral treatment.
- E 13. Any severe acute or chronic medical condition which could impair the ability of
the participant to participate to the study or interfere with interpretation of study
results, or participants unable to comply with the study procedures.
- E 14. Absence of signed and dated Institutional Review Board (IRB)-approved
participant informed consent form prior to enrollment into the study.
- E 15. Participants with reproductive potential who did not agree to use accepted and
effective method of contraception during the study treatment period.
- E 16. History of hypersensitivity to docetaxel, or polysorbate 80.
- E 17. Inadequate organ and bone marrow function
- E 18. Contraindications to the use of corticosteroid treatment.
- E 19. Symptomatic peripheral neuropathy grade >2 (National Cancer Institute Common
Terminology Criteria [NCI CTCAE] v.4.03).
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/05/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1168
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Investigational Site Number 036016 - Bankstown
Query!
Recruitment hospital [2]
0
0
Investigational Site Number 036008 - Camperdown
Query!
Recruitment hospital [3]
0
0
Investigational Site Number 036015 - Coffs Harbour
Query!
Recruitment hospital [4]
0
0
Investigational Site Number 036001 - Concord
Query!
Recruitment hospital [5]
0
0
Investigational Site Number 036017 - Fitzroy
Query!
Recruitment hospital [6]
0
0
Investigational Site Number 036003 - Herston
Query!
Recruitment hospital [7]
0
0
Investigational Site Number 036010 - Hornsby
Query!
Recruitment hospital [8]
0
0
Investigational Site Number 036012 - Kurralta Park
Query!
Recruitment hospital [9]
0
0
Investigational Site Number 036002 - Parkville
Query!
Recruitment hospital [10]
0
0
Investigational Site Number 036009 - South Brisbane
Query!
Recruitment hospital [11]
0
0
Investigational Site Number 036011 - Subiaco
Query!
Recruitment hospital [12]
0
0
Investigational Site Number 036013 - Wodonga
Query!
Recruitment postcode(s) [1]
0
0
2200 - Bankstown
Query!
Recruitment postcode(s) [2]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [3]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [4]
0
0
2137 - Concord
Query!
Recruitment postcode(s) [5]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [6]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [7]
0
0
2077 - Hornsby
Query!
Recruitment postcode(s) [8]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [9]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [10]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [11]
0
0
6008 - Subiaco
Query!
Recruitment postcode(s) [12]
0
0
3690 - Wodonga
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maryland
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
New Jersey
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Mexico
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
North Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Ohio
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Pennsylvania
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Rhode Island
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
South Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Tennessee
Query!
Country [23]
0
0
Belarus
Query!
State/province [23]
0
0
Minsk
Query!
Country [24]
0
0
Belarus
Query!
State/province [24]
0
0
Vitebsk
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Passo Fundo
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Porto Alegre
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Rio De Janeiro
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Sao Jose Do Rio Preto
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Sao Paulo
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Uberlandia
Query!
Country [31]
0
0
Canada
Query!
State/province [31]
0
0
London
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Mississauga
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
Moncton
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Montreal
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Toronto
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Beijing
Query!
Country [38]
0
0
China
Query!
State/province [38]
0
0
Shanghai
Query!
Country [39]
0
0
Czechia
Query!
State/province [39]
0
0
Brno
Query!
Country [40]
0
0
Czechia
Query!
State/province [40]
0
0
Novy Jicin
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Olomouc
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Praha 2
Query!
Country [43]
0
0
Denmark
Query!
State/province [43]
0
0
Herlev
Query!
Country [44]
0
0
Denmark
Query!
State/province [44]
0
0
København Ø
Query!
Country [45]
0
0
Denmark
Query!
State/province [45]
0
0
Odense C
Query!
Country [46]
0
0
Denmark
Query!
State/province [46]
0
0
Ålborg
Query!
Country [47]
0
0
Finland
Query!
State/province [47]
0
0
Helsinki
Query!
Country [48]
0
0
Finland
Query!
State/province [48]
0
0
Kuopio
Query!
Country [49]
0
0
Finland
Query!
State/province [49]
0
0
Turku
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Besancon Cedex
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Bordeaux Cedex
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Caen Cedex 05
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Lyon
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Paris Cedex 05
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Paris Cedex 10
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Paris Cedex 15
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Poitiers Cedex
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Suresnes
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Villejuif
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Aachen
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Berlin
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Düsseldorf
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Erlangen
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Homburg
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
München
Query!
Country [66]
0
0
Israel
Query!
State/province [66]
0
0
Kfar Saba
Query!
Country [67]
0
0
Israel
Query!
State/province [67]
0
0
Petah-Tikva
Query!
Country [68]
0
0
Israel
Query!
State/province [68]
0
0
Tel Aviv
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Arezzo
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Bari
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Orbassano
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Roma
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Trento
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Bunkyo-Ku
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Chiba-Shi
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Kashiwa-Shi
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Koto-Ku
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Osaka Sayama-Shi
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Osaka-Shi
Query!
Country [80]
0
0
Mexico
Query!
State/province [80]
0
0
Acapulco
Query!
Country [81]
0
0
Mexico
Query!
State/province [81]
0
0
Aguascalientes
Query!
Country [82]
0
0
Mexico
Query!
State/province [82]
0
0
D.f.
Query!
Country [83]
0
0
Mexico
Query!
State/province [83]
0
0
Guadalajara
Query!
Country [84]
0
0
Mexico
Query!
State/province [84]
0
0
Merida
Query!
Country [85]
0
0
Mexico
Query!
State/province [85]
0
0
Queretaro
Query!
Country [86]
0
0
Mexico
Query!
State/province [86]
0
0
San Luis Potosi
Query!
Country [87]
0
0
Mexico
Query!
State/province [87]
0
0
Zapopan
Query!
Country [88]
0
0
Peru
Query!
State/province [88]
0
0
Lima
Query!
Country [89]
0
0
Poland
Query!
State/province [89]
0
0
Bydgoszcz
Query!
Country [90]
0
0
Poland
Query!
State/province [90]
0
0
Gdansk
Query!
Country [91]
0
0
Poland
Query!
State/province [91]
0
0
Koscierzyna
Query!
Country [92]
0
0
Poland
Query!
State/province [92]
0
0
Lodz
Query!
Country [93]
0
0
Poland
Query!
State/province [93]
0
0
Poznan
Query!
Country [94]
0
0
Portugal
Query!
State/province [94]
0
0
Coimbra
Query!
Country [95]
0
0
Portugal
Query!
State/province [95]
0
0
Lisboa
Query!
Country [96]
0
0
Portugal
Query!
State/province [96]
0
0
Porto
Query!
Country [97]
0
0
Romania
Query!
State/province [97]
0
0
Baia Mare
Query!
Country [98]
0
0
Romania
Query!
State/province [98]
0
0
Bucharest
Query!
Country [99]
0
0
Romania
Query!
State/province [99]
0
0
Bucuresti
Query!
Country [100]
0
0
Romania
Query!
State/province [100]
0
0
Cluj Napoca
Query!
Country [101]
0
0
Romania
Query!
State/province [101]
0
0
Hunedoara
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
Ekaterinburg
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Moscow
Query!
Country [104]
0
0
Russian Federation
Query!
State/province [104]
0
0
Omsk
Query!
Country [105]
0
0
Russian Federation
Query!
State/province [105]
0
0
Pyatigorsk
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Ryazan
Query!
Country [107]
0
0
Russian Federation
Query!
State/province [107]
0
0
St-Petersburg
Query!
Country [108]
0
0
Russian Federation
Query!
State/province [108]
0
0
Tomsk
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Yaroslavl
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Barcelona
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Hospitalet De Llobregat
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Madrid
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Santiago De Compostela
Query!
Country [114]
0
0
Sweden
Query!
State/province [114]
0
0
Malmö
Query!
Country [115]
0
0
Sweden
Query!
State/province [115]
0
0
Stockholm
Query!
Country [116]
0
0
Sweden
Query!
State/province [116]
0
0
Uppsala
Query!
Country [117]
0
0
Taiwan
Query!
State/province [117]
0
0
Kaohsiung
Query!
Country [118]
0
0
Taiwan
Query!
State/province [118]
0
0
Taichung
Query!
Country [119]
0
0
Taiwan
Query!
State/province [119]
0
0
Taipei
Query!
Country [120]
0
0
Taiwan
Query!
State/province [120]
0
0
Tao-Yuan
Query!
Country [121]
0
0
Turkey
Query!
State/province [121]
0
0
Ankara
Query!
Country [122]
0
0
Turkey
Query!
State/province [122]
0
0
Istanbul
Query!
Country [123]
0
0
Ukraine
Query!
State/province [123]
0
0
Cherkasy
Query!
Country [124]
0
0
Ukraine
Query!
State/province [124]
0
0
Dnipropetrovsk
Query!
Country [125]
0
0
Ukraine
Query!
State/province [125]
0
0
Donetsk
Query!
Country [126]
0
0
Ukraine
Query!
State/province [126]
0
0
Ivano-Frankivsk
Query!
Country [127]
0
0
Ukraine
Query!
State/province [127]
0
0
Kharkov
Query!
Country [128]
0
0
Ukraine
Query!
State/province [128]
0
0
Kyiv
Query!
Country [129]
0
0
Ukraine
Query!
State/province [129]
0
0
Lutsk
Query!
Country [130]
0
0
Ukraine
Query!
State/province [130]
0
0
Uzhgorod
Query!
Country [131]
0
0
Ukraine
Query!
State/province [131]
0
0
Zaporizhzhya
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective:
- To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m^2 (Arm A) or 20
mg/m^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS)
in participants with metastatic castration resistant prostate cancer (mCRPC) and not
previously treated with chemotherapy.
Secondary Objectives:
- To evaluate safety in the 3 treatment arms.
- To compare efficacy of cabazitaxel at 20 mg/m^2 and 25 mg/m^2 to docetaxel for:
- Progression Free Survival (PFS) (RECIST 1.1)
- Tumor progression free survival (RECIST 1.1)
- Tumor response in participants with measurable disease (RECIST 1.1),
- PSA response
- PSA-Progression free survival (PSA-PFS).
- Pain response in participants with stable pain at baseline
- Pain progression free survival
- Time to occurrence of any skeletal related events (SRE)
- To compare Health-Related Quality of Life (HRQL).
- To assess the pharmacokinetics and pharmacogenomics of cabazitaxel.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01308567
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01308567
Download to PDF